Stem Cell Therapeutics Announces Favorable Results From The Phase IIa BETAS Stroke Trial

Stem Cell Therapeutics Corp. (”SCT”) (TSX VENTURE:SSS) is pleased to announce favorable results from the investigator led BETAS (Beta-hCG + Erythropoietin in Acute Stroke), Phase IIa, open label, safety trial conducted at the University of California, Irvine and Hoag Presbyterian Memorial Hospital, Newport Beach, CA.

More: continued here

Filed under: Clinical Trials on February 26th, 2008